|
A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Betta Pharmaceuticals |
Leadership - Betta Pharmaceuticals |
Stock and Other Ownership Interests - Betta Pharmaceuticals |
Honoraria - Betta Pharmaceuticals |
Consulting or Advisory Role - Betta Pharmaceuticals |
Speakers' Bureau - Betta Pharmaceuticals |
Research Funding - Betta Pharmaceuticals (Inst) |
Patents, Royalties, Other Intellectual Property - Betta Pharmaceuticals |
Expert Testimony - Betta Pharmaceuticals |
Travel, Accommodations, Expenses - Betta Pharmaceuticals |
|
|
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere |